SCHEMBL1870769

SCHEMBL1870769

NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 14/20 1.00
SIRT2 Q8IXJ6 5/20 1.00
SIRT3 Q9NTG7 2/20 1.00
RECQL P46063 1/20 0.73
ALOX15 P16050 4/20 0.72
MEN1 O00255 4/20 0.72
KMT2A Q03164 4/20 0.72
TSHR P16473 1/20 0.72
SMN1; SMN2 Q16637 3/20 0.69
LMNA P02545 2/20 0.69
TP53 P04637 1/20 0.69
MAPT P10636 3/20 0.69
MAPK1 P28482 1/20 0.69
KDM4E B2RXH2 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
GLA P06280 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1275557 1.00 SIRT1 (1.00) SIRT1SIRT2SIRT3RECQLALOX15
SCHEMBL1874310 1.00 SIRT1 (1.00) SIRT1SIRT2SIRT3RECQLALOX15
SCHEMBL8251110 0.96 SIRT1 (1.00) SIRT1SIRT2SIRT3RECQLALOX15
SCHEMBL8257650 0.96 SIRT1 (1.00) SIRT1SIRT2SIRT3RECQLALOX15
SCHEMBL1873844 0.96 SIRT1 (1.00) SIRT1SIRT2SIRT3RECQLALOX15
SCHEMBL3484154 0.92 SIRT1 (1.00) SIRT1SIRT2SIRT3RECQLALOX15
SCHEMBL1674922 0.88 SIRT1 (0.79) SIRT1SIRT2SIRT3ALOX15MEN1
SCHEMBL12989489 0.87 SIRT1 (0.77) SIRT1SIRT2SIRT3RECQLALOX15
SCHEMBL12990011 0.87 SIRT1 (0.77) SIRT1SIRT2SIRT3RECQLALOX15
SCHEMBL15353959 0.86 MEN1 (0.77) SIRT1SIRT2SIRT3RECQLALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 503 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180140722-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF HEART FAILURE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-05-24 US claimed
EP-4746408-A2 IMAGE CODING METHOD, IMAGE DECODING METHOD, MEMORY MANAGING METHOD, IMAGE CODING APPARATUS, IMAGE DECODING APPARATUS, MEMORY MANAGING APPARATUS, AND IMAGE CODING AND DECODING APPARATUS Sun Patent Trust (US) 2026-05-20 EP disclosed
CN-115955853-B Organic light emitting diode and organic light emitting device including the same 乐金显示有限公司 2026-05-15 CN disclosed
EP-4465629-B1 IMAGE CODING AND DECODING SUN PATENT TRUST (US) 2026-05-13 EP disclosed
EP-3723754-B1 IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME LLC (US) 2026-05-13 EP disclosed
EP-4734515-A2 IMAGE ENCODING METHOD, IMAGE DECODING METHOD, IMAGE ENCODING DEVICE, IMAGE DECODING DEVICE, AND IMAGE CODING-DECODING DEVICE Sun Patent Trust (US) 2026-04-29 EP disclosed
EP-2822277-B1 IMAGE CODING METHOD, IMAGE DECODING METHOD, IMAGE CODING DEVICE, IMAGE DECODING DEVICE, AND IMAGE CODING-DECODING DEVICE SUN PATENT TRUST (US) 2026-04-22 EP disclosed
EP-4729510-A1 INDOLE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Suzhou Merna Therapeutics Co. Ltd (CN) 2026-04-22 EP disclosed
EP-4730804-A2 VIDEO DECODING METHOD, VIDEO DECODING DEVICE Sun Patent Trust (US) 2026-04-22 EP disclosed
US-12610069-B2 Image decoding method, image coding method, image decoding apparatus, image coding apparatus, and image coding and decoding apparatus SUN PATENT TRUST (US) 2026-04-21 US disclosed
US-20090022694-A1 SIRT1 INHIBITION ELIXIR PHARMACEUTICALS, INC. 2009-01-22 US disclosed
US-20090022694-A1 SIRT1 INHIBITION ELIXIR PHARMACEUTICALS, INC. 2009-01-22 US disclosed
US-20080214800-A1 Deacetylase which uses NAD as a cofactor; treating sirtuin related disorders ELIXIR PHARMACEUTICALS, INC. 2008-09-04 US disclosed
US-20080214800-A1 Deacetylase which uses NAD as a cofactor; treating sirtuin related disorders ELIXIR PHARMACEUTICALS, INC. 2008-09-04 US disclosed
WO-2008082646-A2 HISTONE DEACETYLASE INHIBITORS, COMBINATION THERAPIES AND METHODS OF USE THE JOHNS HOPKINS UNIVERSITY (US) 2008-07-10 WO disclosed
EP-1891949-A1 Use of tricyclic indole derivatives for the treatment of muscular atrophy Santhera Pharmaceuticals (Schweiz) AG (CH) 2008-02-27 EP disclosed
WO-2008019825-A1 USE OF TRICYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF MUSCULAR DISEASES SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2008-02-21 WO disclosed
WO-2007047604-A2 SIRT1 INHIBITION ELIXIR PHARMACEUTICALS, INC. (US) 2007-04-26 WO disclosed
WO-2006031894-A2 METHODS OF TREATING A DISORDER ELIXIR PHARMACEUTICALS, INC. (US) 2006-03-23 WO disclosed
WO-2005026112-A2 METHODS OF TREATING A DISORDER ELIXIR PHARMACEUTICALS, INC. (US) 2005-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12610069-B2 Image decoding method, image coding method, image decoding apparatus, image coding apparatus, and image coding and decoding apparatus CBFB, CHRNA10, MYBBP1A SIRT1 4456/4885SIRT2 4538/4885SIRT3 4600/4885
US-20080214800-A1 Deacetylase which uses NAD as a cofactor; treating sirtuin related disorders SIRT3, SIRT1, SIRT2 SIRT1 2/4885SIRT2 3/4885SIRT3 1/4885
US-20090022694-A1 SIRT1 INHIBITION SIRT1, SIRT2, SIRT3 SIRT1 1/4885SIRT2 2/4885SIRT3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.